Zhongzhu Medical Holdings Co Ltd (600568) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhongzhu Medical Holdings Co Ltd (600568) has a cash flow conversion efficiency ratio of 0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.78 Million ≈ $3.92 Million USD) by net assets (CN¥1.71 Billion ≈ $250.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Zhongzhu Medical Holdings Co Ltd balance sheet quality to measure how much of total assets are equity-financed.
Zhongzhu Medical Holdings Co Ltd - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Zhongzhu Medical Holdings Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 600568 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Zhongzhu Medical Holdings Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhongzhu Medical Holdings Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cognyte Software Ltd
NASDAQ:CGNT
|
0.095x |
|
JINXIN FERT.GRP HD-00001
F:3NX
|
N/A |
|
China Building Material
SHG:603060
|
0.043x |
|
Chapters Group AG
XETRA:CHG
|
0.040x |
|
Vitesse Energy Inc
NYSE:VTS
|
0.042x |
|
Shenzhen Exc Led Technology Co Ltd
SHE:300889
|
-0.024x |
|
Beijing Beilu Pharmaceutical
SHE:300016
|
0.032x |
|
Valor Estate Limited
NSE:DBREALTY
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Zhongzhu Medical Holdings Co Ltd (1999–2025)
The table below shows the annual cash flow conversion efficiency of Zhongzhu Medical Holdings Co Ltd from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Zhongzhu Medical Holdings Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.63 Billion ≈ $238.63 Million |
CN¥56.08 Million ≈ $8.21 Million |
0.034x | +83.70% |
| 2024-12-31 | CN¥1.74 Billion ≈ $255.02 Million |
CN¥32.63 Million ≈ $4.77 Million |
0.019x | +1649.82% |
| 2023-12-31 | CN¥2.59 Billion ≈ $379.07 Million |
CN¥2.77 Million ≈ $405.57K |
0.001x | -87.69% |
| 2022-12-31 | CN¥2.94 Billion ≈ $429.73 Million |
CN¥25.52 Million ≈ $3.74 Million |
0.009x | -65.54% |
| 2021-12-31 | CN¥3.73 Billion ≈ $545.62 Million |
CN¥94.04 Million ≈ $13.76 Million |
0.025x | -59.55% |
| 2020-12-31 | CN¥3.98 Billion ≈ $582.38 Million |
CN¥248.15 Million ≈ $36.31 Million |
0.062x | -60.51% |
| 2019-12-31 | CN¥3.89 Billion ≈ $569.54 Million |
CN¥614.57 Million ≈ $89.93 Million |
0.158x | +351.03% |
| 2018-12-31 | CN¥4.26 Billion ≈ $622.92 Million |
CN¥-267.76 Million ≈ $-39.18 Million |
-0.063x | -7.91% |
| 2017-12-31 | CN¥6.15 Billion ≈ $899.41 Million |
CN¥-358.29 Million ≈ $-52.43 Million |
-0.058x | -218.18% |
| 2016-12-31 | CN¥6.01 Billion ≈ $879.82 Million |
CN¥296.58 Million ≈ $43.40 Million |
0.049x | -30.98% |
| 2015-12-31 | CN¥2.65 Billion ≈ $387.06 Million |
CN¥189.05 Million ≈ $27.66 Million |
0.071x | +1185.81% |
| 2014-12-31 | CN¥2.58 Billion ≈ $377.47 Million |
CN¥14.34 Million ≈ $2.10 Million |
0.006x | +84.24% |
| 2013-12-31 | CN¥1.18 Billion ≈ $172.51 Million |
CN¥3.56 Million ≈ $520.44K |
0.003x | +106.40% |
| 2012-12-31 | CN¥1.03 Billion ≈ $150.39 Million |
CN¥-48.43 Million ≈ $-7.09 Million |
-0.047x | +42.30% |
| 2011-12-31 | CN¥915.88 Million ≈ $134.02 Million |
CN¥-74.80 Million ≈ $-10.94 Million |
-0.082x | +88.58% |
| 2010-12-31 | CN¥742.77 Million ≈ $108.69 Million |
CN¥-531.24 Million ≈ $-77.74 Million |
-0.715x | -91.30% |
| 2009-12-31 | CN¥677.27 Million ≈ $99.11 Million |
CN¥-253.20 Million ≈ $-37.05 Million |
-0.374x | -353.89% |
| 2008-12-31 | CN¥616.24 Million ≈ $90.17 Million |
CN¥90.74 Million ≈ $13.28 Million |
0.147x | +2020.96% |
| 2007-12-31 | CN¥514.98 Million ≈ $75.36 Million |
CN¥3.58 Million ≈ $523.18K |
0.007x | -93.14% |
| 2006-12-31 | CN¥479.24 Million ≈ $70.13 Million |
CN¥48.49 Million ≈ $7.10 Million |
0.101x | -1.27% |
| 2005-12-31 | CN¥558.76 Million ≈ $81.76 Million |
CN¥57.27 Million ≈ $8.38 Million |
0.102x | +1726.33% |
| 2004-12-31 | CN¥489.48 Million ≈ $71.63 Million |
CN¥2.75 Million ≈ $401.95K |
0.006x | +380.94% |
| 2003-12-31 | CN¥472.91 Million ≈ $69.20 Million |
CN¥551.80K ≈ $80.75K |
0.001x | -8.44% |
| 2002-12-31 | CN¥444.66 Million ≈ $65.07 Million |
CN¥566.66K ≈ $82.92K |
0.001x | -87.95% |
| 2001-12-31 | CN¥433.47 Million ≈ $63.43 Million |
CN¥4.59 Million ≈ $671.09K |
0.011x | -69.40% |
| 2000-12-31 | CN¥82.36 Million ≈ $12.05 Million |
CN¥2.85 Million ≈ $416.77K |
0.035x | -64.08% |
| 1999-12-31 | CN¥69.76 Million ≈ $10.21 Million |
CN¥6.72 Million ≈ $982.65K |
0.096x | -- |
About Zhongzhu Medical Holdings Co Ltd
Zhongzhu Healthcare Holding Co.,Ltd engages in the research and development, production, and sale of drugs in China. The company offers ophthalmology drugs, including Pearl eye drops, Sodium Cromolyn eye drops, Acyclovir eye drops, Hydroxybenzone Hydrochloride eye drops, Acyclovir dispersible tablets, and Gatifloxacin tablets; and products related to tumor treatment. It is also involved in produc… Read more